Reported 1 day ago
Adaptive Biotechnologies (ADPT) announced the termination of its strategic collaboration and license agreement with Genentech, effective February 9, 2026. This decision allows the company to avoid exclusive obligations regarding oncology cell therapies and will result in a $33.7 million non-cash revenue boost in the latter half of the year. Following this change, Adaptive Biotechnologies will continue to focus on its Immune Medicine programs and advance its digital TCR-antigen prediction models.
Source: YAHOO